Search | Clinical Trials Finder

Conditions: NSCLC
Interventions: Poziotinib, Docetaxel; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Winter Haven, Florida

Conditions: Untreated Advanced Non-Small Cell Lung Cancer
Interventions: Avastin, Alimta; Drug
Lead sponsor: The Cooper Health System; Other
Eligibility: 18 Years and older
U.S. locations: 1
States / cities: Voorhees Township, New Jersey

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Durvalumab; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Gainesville, Georgia • Knoxville, Tennessee

Conditions: Advanced Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Lung Neoplasms
Interventions: Vigil™, Nivolumab; Biological · Drug
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Abilene, Texas • Dallas, Texas • Spokane Valley, Washington

Conditions: Advanced Cancer
Interventions: Avelumab, Utomilumab, PF-04518600, PD 0360324, CMP-001; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 57
States / cities: Encinitas, California • La Jolla, California • Los Angeles, California + 23 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Vinorelbine, Docetaxel, Gemcitabine, Carboplatin; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Advanced Cancer
Interventions: FLX475 (tivumecirnon), pembrolizumab (KEYTRUDA®); Drug
Lead sponsor: RAPT Therapeutics, Inc., a member of the GSK plc group of companies; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 19
States / cities: Gilbert, Arizona • Duarte, California • Los Angeles, California + 16 more

Conditions: Non-small Cell Lung Cancer Metastatic
Interventions: Nivolumab + Plinabulin; Drug
Lead sponsor: Lyudmila Bazhenova, M.D.; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, cisplatin, etoposide; Radiation · Drug
Lead sponsor: University of Washington; Other
Eligibility: Not listed
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non Small Cell Lung Cancer
Interventions: Mapatumumab, Paclitaxel, Carboplatin; Biological · Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 16
States / cities: Birmingham, Alabama • Rancho Mirage, California • Aurora, Colorado + 13 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Savolitinib, Osimertinib, Pemetrexed, Cisplatin, Carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Orlando, Florida • Honolulu, Hawaii • New Brunswick, New Jersey + 2 more

Conditions: Lung Cancer, Perioperative/Postoperative Complications, Pulmonary Complications, Tobacco Use Disorder
Interventions: exercise intervention, smoking cessation intervention, counseling intervention, educational intervention, conventional surgery, pulmonary complications management/prevention; Behavioral · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer
Interventions: allogeneic tumor cell vaccine, autologous tumor cell vaccine, recombinant interferon alfa, recombinant interferon gamma, sargramostim, cyclophosphamide; Biological · Drug
Lead sponsor: St. Vincent Medical Center - Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Lung Cancer
Interventions: Gemcitabine, Pemetrexed, Surgery; Drug · Procedure
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Non-Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: laboratory biomarker analysis, questionnaire administration; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma
Interventions: Genomically Guided Radiation Therapy (RT); Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lung Cancer
Interventions: carboplatin, celecoxib, gemcitabine hydrochloride, pemetrexed disodium, placebo; Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 313 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 400
States / cities: Anniston, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 266 more

Conditions: Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage I Lung Cancer AJCC v8
Interventions: Computed Tomography, Indocyanine Green Solution, Therapeutic Bronchoscopy; Procedure · Drug · Device
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC)
Interventions: XB010, Pembrolizumab; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 16
States / cities: Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 12 more

Conditions: Solid Tumor
Interventions: Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Cisplatin, Investigator's choice of platinum agent; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more

Conditions: Recurrent Non-Small Cell Lung Cancer
Interventions: MV-NIS, Atezolizumab; Biological
Lead sponsor: Vyriad, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer
Interventions: Cetuximab, Conformal Thoracic Radiotherapy (CTRT); Drug · Radiation
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Echocardiography Test, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Observation Activity, Paclitaxel, Pembrolizumab, Pemetrexed Disodium, Questionnaire Administration; Procedure · Drug · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1,210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1150
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Gilbert, Arizona + 747 more

Search by objective public record fields.

A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations

Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

The 'MADe IT' Clinical Trial: Molecular Analyses Directed Individualized Therapy for Advanced Non-Small Cell Lung Cancer

Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Lung Rehabilitation in Treating Patients With Chronic Obstructive Pulmonary Disease Who Are Undergoing Surgery for Lung Cancer

Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer

Pharmacogenomic & Phase II Study of Gemcitabine and Pemetrexed in Non-Small-Cell Lung Cancer.

Using Imaging and Molecular Markers to Predict Tumor Response and Lung Toxicity in Lung Cancer

Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor

Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Robotic Bronchoscopy With Cone CT and Indocyanine Green to Aid Removal of Lung Lesions in Patients With Stage I Non-small Cell Lung Cancer or Lung Metastases, REPLACING Study

Study of XB010 in Subjects With Solid Tumors

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])